NeoGenomics, Inc. Equity-NMS: NEO

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$10.21

1Y :

-77.09%

5Y :

14.7%

What is the share price of NeoGenomics, Inc. today?

NeoGenomics, Inc. (NEO) share price as of August 8, 2022, is $10.23. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of NeoGenomics, Inc.?

Yes, Indian Investors can invest in the NeoGenomics, Inc. (NEO) Share by opening an international trading account with Angel One.

How can I purchase NeoGenomics, Inc. shares in India?

Purchasing NeoGenomics, Inc. (NEO) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying NeoGenomics, Inc. (NEO) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of NeoGenomics, Inc.?

Yes, you can purchase fractional shares of NeoGenomics, Inc. (NEO) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of NeoGenomics, Inc.?

The market capitalization of NeoGenomics, Inc. on August 9, 2022, is $0.

In which sector NeoGenomics, Inc. belongs?

NeoGenomics, Inc. operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in NeoGenomics, Inc. stocks?

In order to invest in NeoGenomics, Inc. (NEO) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. It offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.